Crinetics Pharmaceuticals Inc. (CRNX) Financial Statements (2024 and earlier)

Company Profile

Business Address 10222 BARNES CANYON ROAD, BLDG. #2
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:558,600334,400333,700170,900118,400163,900
Cash and cash equivalents54,89732,672200,69593,08740,32644,973
Short-term investments503,658301,753133,01277,79378,066118,902
Other undisclosed cash, cash equivalents, and short-term investments45(25)(7)20825
Receivables3,1411,4881,052113449568
Prepaid expense857939888693  
Other current assets1,5782,5359121,0241,0911,224
Other undisclosed current assets9,9775,8228,1684,7623,399991
Total current assets:574,153345,184344,720177,492123,339166,683
Noncurrent Assets
Operating lease, right-of-use asset46,5491,4861,8922,2322,510
Property, plant and equipment10,8813,5002,8253,1813,9464,232
Restricted cash and investments1,3001,301500500500500
Other noncurrent assets2,00037 4082 
Other undisclosed noncurrent assets 4706681,078   
Total noncurrent assets:61,2006,9926,2955,9537,0384,732
TOTAL ASSETS:635,353352,176351,015183,445130,377171,415
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:23,19615,3518,4685,5885,4987,925
Employee-related liabilities   2,279
Accounts payable6,5486,883   1,456
Accrued liabilities3,267694   4,190
Other undisclosed accounts payable and accrued liabilities13,3817,7748,4685,5885,498 
Deferred revenue  2,200   
Debt     724 
Other liabilities  1,051939835724 
Other undisclosed current liabilities20,7469,1216,5884,0661,394 
Total current liabilities:43,94227,72315,99510,4898,3407,925
Noncurrent Liabilities
Long-term debt and lease obligation:   3,0744,0144,849 
Liabilities, other than long-term debt52,3058,125223493,265
Deferred revenue4,7506,101   
Deferred compensation liability, classified   22349202
Deferred rent credit      3,063
Operating lease, liability47,5552,0243,0744,0144,849
Total noncurrent liabilities:52,3058,1253,0764,0374,8983,265
Total liabilities:96,24735,84819,07114,52613,23811,190
Equity
Equity, attributable to parent, including:539,106316,328331,944168,919117,139160,225
Common stock253    24
Additional paid in capital      203,520
Accumulated other comprehensive income (loss)977(3,931)(382)2514861
Accumulated deficit(653,702)(439,173)(275,255)(167,614)(93,802)(43,380)
Other undisclosed equity, attributable to parent1,191,578759,432607,581336,508210,793 
Total equity:539,106316,328331,944168,919117,139160,225
TOTAL LIABILITIES AND EQUITY:635,353352,176351,015183,445130,377171,415

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues4,0134,7371,078711,1932,428
Gain on disposition of assets for financial service operations   2,000   
Gross profit:4,0134,7371,078711,1932,428
Operating expenses(226,621)(172,619)(108,780)(75,024)(55,025)(31,138)
Operating loss:(222,608)(167,882)(107,702)(74,953)(53,832)(28,710)
Nonoperating income13,2774,974611,1413,4101,595
Investment income, nonoperating13,4364,3171579913,4601,748
Loss from continuing operations before equity method investments, income taxes:(209,331)(162,908)(107,641)(73,812)(50,422)(27,115)
Other undisclosed loss from continuing operations before income taxes(5,198)(1,010)    
Loss from continuing operations:(214,529)(163,918)(107,641)(73,812)(50,422)(27,115)
Loss before gain (loss) on sale of properties:(107,641)(73,812)(50,422)(27,115)
Net loss:(214,529)(163,918)(107,641)(73,812)(50,422)(27,115)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(214,529)(163,918)(107,641)(73,812)(50,422)(27,115)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(214,529)(163,918)(107,641)(73,812)(50,422)(27,115)
Other comprehensive income (loss)(4,908)(3,549)(407)(123)8761
Comprehensive loss:(219,437)(167,467)(108,048)(73,935)(50,335)(27,054)
Other undisclosed comprehensive income, net of tax, attributable to parent9,816     
Comprehensive loss, net of tax, attributable to parent:(209,621)(167,467)(108,048)(73,935)(50,335)(27,054)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: